

Cyto Pulse Sciences, Inc. Awarded Grant by Maryland Technology Development Corporation for a Smallpox DNA Vaccine Delivery Project



Website

GLEN BURNIE, Md., Feb. 2 /PRNewswire/ -- The Maryland Technology Development Corporation (TEDCO) has awarded a \$50,000 grant to Cyto Pulse Sciences, Inc., of Glen Burnie, MD for a project to be conducted under the Ft. Detrick Technology Transfer Initiative (FDTTI).

The project is entitled "Delivery of Four Vaccinia DNA Genes Simultaneously Using Easy Vax(TM)."

Easy Vax(TM) is the Cyto Pulse trademark for a DNA vaccine delivery system that uses an array of hundreds of short needles, each one coated with the DNA vaccine. An electric field allows the DNA to enter cells in the skin including dendritic cells involved in immune system response.

The FDTTI program supports both the development of commercial technologies by private sector companies to meet the medical needs of the U.S. Army, and the commercialization of technologies developed in the U.S. Army Medical Research and Materiel Command's research laboratories.

The funding Cyto Pulse received is specifically directed at developing a technique to deliver several different DNA vaccines simultaneously on a single array. This project is complementary to the ongoing work under a Cooperative Research and Development Agreement to evaluate the Easy Vax system for delivery of the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) smallpox DNA vaccine.

"We are very pleased to have this new relationship with TEDCO and we look forward to advancing this very promising medical technology," said Richard E. Walters, Cyto Pulse CEO.

Cyto Pulse Sciences, Inc. is a medical device and treatment development company offering innovative technology for clinical therapeutic applications including delivery of DNA vaccines. The company was founded in 1996 with the goal of developing clinical systems employing electric fields to create gene therapy and immunotherapeutic treatments unattainable by chemical or viral vectors. Its devices enable cellular material transfers and fusion with a degree of safety, repeatability and efficiency suitable for clinical use and laboratory research in gene therapy, immunotherapy, and hybridoma production.

Additional information on Cyto Pulse Sciences, Inc. is available at the company's website, <http://www.cytopulse.com>.

SOURCE Cyto Pulse Sciences, Inc.
Web Site: <http://www.cytopulse.com>

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996- 2006 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company.